CN104302309B - Ctla‑4变体 - Google Patents

Ctla‑4变体 Download PDF

Info

Publication number
CN104302309B
CN104302309B CN201380024763.3A CN201380024763A CN104302309B CN 104302309 B CN104302309 B CN 104302309B CN 201380024763 A CN201380024763 A CN 201380024763A CN 104302309 B CN104302309 B CN 104302309B
Authority
CN
China
Prior art keywords
ctla
seq
polypeptide
amino acid
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380024763.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104302309A (zh
Inventor
R·敏特尔
J·杜思韦特
J·莫桑
M·鲍恩
S·拉斯特
C·普里韦曾特夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Vaccines Inc
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CN201710735648.7A priority Critical patent/CN107540742B/zh
Publication of CN104302309A publication Critical patent/CN104302309A/zh
Application granted granted Critical
Publication of CN104302309B publication Critical patent/CN104302309B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/425—Zeins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380024763.3A 2012-05-11 2013-03-11 Ctla‑4变体 Active CN104302309B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710735648.7A CN107540742B (zh) 2012-05-11 2013-03-11 Ctla-4变体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645686P 2012-05-11 2012-05-11
US61/645,686 2012-05-11
PCT/US2013/030179 WO2013169338A1 (en) 2012-05-11 2013-03-11 Ctla-4 variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710735648.7A Division CN107540742B (zh) 2012-05-11 2013-03-11 Ctla-4变体

Publications (2)

Publication Number Publication Date
CN104302309A CN104302309A (zh) 2015-01-21
CN104302309B true CN104302309B (zh) 2017-07-28

Family

ID=49551120

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710735648.7A Active CN107540742B (zh) 2012-05-11 2013-03-11 Ctla-4变体
CN201380024763.3A Active CN104302309B (zh) 2012-05-11 2013-03-11 Ctla‑4变体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710735648.7A Active CN107540742B (zh) 2012-05-11 2013-03-11 Ctla-4变体

Country Status (17)

Country Link
US (2) US9884902B2 (enExample)
EP (2) EP2863936A4 (enExample)
JP (1) JP6228971B2 (enExample)
KR (1) KR102133060B1 (enExample)
CN (2) CN107540742B (enExample)
AU (1) AU2013260172B2 (enExample)
BR (1) BR112014026718B1 (enExample)
CA (1) CA2868748C (enExample)
DK (1) DK3207938T3 (enExample)
ES (1) ES2777778T3 (enExample)
HK (1) HK1209644A1 (enExample)
HU (1) HUE048925T2 (enExample)
MX (2) MX355234B (enExample)
PL (1) PL3207938T3 (enExample)
RU (1) RU2671465C2 (enExample)
SG (2) SG11201405968SA (enExample)
WO (1) WO2013169338A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119857A1 (de) 1991-06-17 1992-12-24 Basf Lacke & Farben Ueberzugsmittel auf der basis von carboxylgruppenhaltigen polymeren und epoxidharzen
AU2013260172B2 (en) * 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants
WO2014004780A1 (en) * 2012-06-29 2014-01-03 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
US9944689B2 (en) * 2013-03-07 2018-04-17 The General Hospital Corporation Human CTLA4 mutants and use thereof
WO2015113494A1 (zh) * 2014-01-28 2015-08-06 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
US10689423B2 (en) 2015-01-13 2020-06-23 City Of Hope CTLA4-binding protein peptide-linker masks
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR20240046641A (ko) 2015-04-17 2024-04-09 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 친화성을 갖는 면역조절 단백질
CN108137659B (zh) 2015-08-21 2021-11-26 汉阳大学校产学协力团 具有预防或治疗中枢神经系统疾病作用的肽和包含其作为活性成分的药物组合物
WO2017034244A1 (ko) * 2015-08-21 2017-03-02 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
US11351224B2 (en) 2015-08-21 2022-06-07 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Pharmaceutical composition for preventing and treating transplant rejection
KR20180054713A (ko) * 2015-09-14 2018-05-24 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
KR101918456B1 (ko) * 2015-12-15 2018-11-16 앱클론(주) Cd80 및 cd86에 특이적으로 결합하는 항체
MA43551A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants du ligand icos et leurs utilisations
KR102764225B1 (ko) 2016-04-15 2025-02-07 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
KR20190141146A (ko) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l2 변이체 면역조절 단백질 및 그의 용도
IL268781B2 (en) 2017-03-16 2025-09-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
IL322942A (en) 2017-05-24 2025-10-01 Als Therapy Development Inst Therapeutic anti-CD40 ligand antibodies
CN121021670A (zh) * 2017-10-10 2025-11-28 高山免疫科学股份有限公司 Ctla-4变体免疫调节蛋白和其用途
US20200283500A1 (en) 2017-10-18 2020-09-10 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
EP3856247A4 (en) * 2018-11-02 2022-07-06 Beijing Vdjbio Co., Ltd. MODIFIED CTLA4 AND METHODS OF USE
CN113645990B (zh) * 2019-04-10 2025-01-24 肯塔基大学研究基金会 改良的前列腺凋亡反应-4(par-4)多肽及其生产和使用方法
CA3166299A1 (en) * 2020-01-11 2021-07-15 Paul STABACH Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency
PL4045533T3 (pl) 2020-03-26 2024-04-15 Vanderbilt University Ludzkie przeciwciała monoklonalne przeciwko ciężkiemu ostremu zespołowi oddechowemu wywołanemu koronawirusem 2 (sars-cov-2)
EP4132965A2 (en) * 2020-04-06 2023-02-15 Lung Biotechnology PBC Modular synthetic receptors and methods of use
EP4142792A4 (en) 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
CN112661865A (zh) * 2020-12-31 2021-04-16 厚朴生物科技（苏州）有限公司 针对新型冠状病毒的疫苗以及其应用
EP4392156A4 (en) * 2021-10-08 2025-06-25 Kashiv Biosciences, LLC Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
US20250236640A1 (en) * 2021-10-08 2025-07-24 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
AU2022414315A1 (en) * 2021-12-17 2024-07-25 Kashiv Biosciences, Llc An improved assay method for determining the potency of recombinant protein
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058564A2 (en) * 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580812A1 (en) 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1997047732A2 (en) * 1996-06-14 1997-12-18 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
RU2283847C2 (ru) 2000-05-26 2006-09-20 Бристол-Маерс Сквибб Компани Растворимый мутантный ctla4 и его применение
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP4784772B2 (ja) 2005-07-07 2011-10-05 東芝ライテック株式会社 放電灯点灯装置および電球形蛍光ランプ
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
KR101926663B1 (ko) 2010-02-19 2018-12-07 젠코어 인코포레이티드 신규의 ＣＴＬＡ４-Ｉｇ 이뮤노어드헤신
KR20130049775A (ko) * 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
AU2013260172B2 (en) * 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058564A2 (en) * 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Differential effects of CTLA-4 substitutions on the binding of human CD80(B7-1) and CD86(B7-2);Morton et al.;《J Immunol》;19961231;第1047-1054页 *

Also Published As

Publication number Publication date
JP6228971B2 (ja) 2017-11-08
PL3207938T3 (pl) 2020-07-13
HUE048925T2 (hu) 2020-09-28
ES2777778T3 (es) 2020-08-06
US9884902B2 (en) 2018-02-06
CN104302309A (zh) 2015-01-21
CA2868748C (en) 2022-07-26
SG10201609447XA (en) 2017-01-27
RU2671465C2 (ru) 2018-10-31
CN107540742A (zh) 2018-01-05
MX385969B (es) 2025-03-18
BR112014026718B1 (pt) 2021-05-18
AU2013260172B2 (en) 2017-11-23
EP3207938B1 (en) 2019-12-25
EP2863936A4 (en) 2016-10-05
EP3207938A2 (en) 2017-08-23
JP2015523328A (ja) 2015-08-13
SG11201405968SA (en) 2014-11-27
CA2868748A1 (en) 2013-11-14
KR20150014443A (ko) 2015-02-06
US20150104450A1 (en) 2015-04-16
EP2863936A1 (en) 2015-04-29
WO2013169338A1 (en) 2013-11-14
MX355234B (es) 2018-04-11
EP3207938A3 (en) 2017-11-01
AU2013260172A1 (en) 2014-10-23
HK1209644A1 (en) 2016-04-08
DK3207938T3 (da) 2020-03-16
KR102133060B1 (ko) 2020-07-10
BR112014026718A2 (pt) 2017-07-18
US20180208639A1 (en) 2018-07-26
CN107540742B (zh) 2021-06-29
MX2014013092A (es) 2015-03-03
RU2014150092A (ru) 2016-07-10

Similar Documents

Publication Publication Date Title
CN104302309B (zh) Ctla‑4变体
JP6408039B2 (ja) 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
US9834589B2 (en) CD86 variants with improved affinity for CTLA-4
TWI671318B (zh) 介白素－２融合蛋白及其用途
CN113286609B (zh) 多聚体t细胞调节多肽及其使用方法
JP2021090441A (ja) 調整可能な親和性を有する免疫調節タンパク質
CN113474367A (zh) 结合cd3和hla-a*02限制性肽的半衰期延长的immtac
KR20110112299A (ko) 자가면역 및 염증성 장애의 치료에 사용하기 위한 가용성 폴리펩티드
CN106456733A (zh) Syntac多肽及其用途
TW201420607A (zh) 介白素－２融合蛋白及其用途
US20240376177A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
HK1241720A1 (en) Ctla-4 variants
HK1241720B (en) Ctla-4 variants
US20230241192A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
CN121219321A (zh) 与bcma特异性结合的免疫刺激性抗原结合分子
HK40060108B (zh) 多聚体t细胞调节多肽及其使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171214

Address after: Cambridge County

Patentee after: Medimmune Vaccines Inc.

Address before: American Maryland

Co-patentee before: Medimmune Vaccines Inc.

Patentee before: Medimmune Vaccines Inc.